Affiliation:
1. The Medicines Company, Ville St-Laurent, Quebec, Canada
Abstract
ABSTRACT
There are limited therapeutic options to treat infections caused by vancomycin-resistant
Enterococcus faecium
(VREfm). The lipoglycopeptide oritavancin exhibits
in vitro
activity against this pathogen, although its utility against infections caused by VREfm has not been clinically established. In this study, the pharmacodynamic activity of free-drug levels associated with 12 mg/kg/day of daptomycin and a single 1,200-mg dose of oritavancin were determined against three VanA VREfm isolates in an
in vitro
pharmacokinetic/pharmacodynamic model.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献